NCT04567420 2025-10-16
DARE
Criterium, Inc.
Phase 2 Recruiting
Clinical Trials
7 trialsNCT07067268 2025-07-16
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Fudan University
Phase 2 Recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT05296746 2025-03-18
RIBOLARIS
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT05872724 2023-05-24
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
Suzhou Municipal Hospital
Phase 2 Recruiting
NCT05286957 2023-03-17
Seagull
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT05679583 2023-01-11
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
Yonsei University
Phase 2 Recruiting